WTX-124 Phase 1/1b shows 3 objective responses (1 CR) in checkpoint-refractory solid tumors

Werewolf Therapeutics, Inc.

3 objective responses out of 35 monotherapy-treated patients: 1 confirmed complete response, 2 partial responses.
All responding patients had 100% target lesion regression; responses durable at recommended dose for expansion (RDE).
RDE selected as 18 mg IV every 2 weeks; three expansion arms opened in RCC, melanoma, cutaneous SCC.
WTX-124 + pembrolizumab combination well-tolerated with enhanced T-cell activation in tumors; no new safety signals.
Company plans to engage regulators on potential monotherapy accelerated approval pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.